JP2017520774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520774A5 JP2017520774A5 JP2017502940A JP2017502940A JP2017520774A5 JP 2017520774 A5 JP2017520774 A5 JP 2017520774A5 JP 2017502940 A JP2017502940 A JP 2017502940A JP 2017502940 A JP2017502940 A JP 2017502940A JP 2017520774 A5 JP2017520774 A5 JP 2017520774A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- subject
- composition
- measured
- hypoxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021159462A JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972091P | 2014-03-28 | 2014-03-28 | |
| US61/972,091 | 2014-03-28 | ||
| PCT/US2015/023038 WO2015148950A1 (en) | 2014-03-28 | 2015-03-27 | L-2-hydroxyglutarate and stress induced metabolism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159462A Division JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520774A JP2017520774A (ja) | 2017-07-27 |
| JP2017520774A5 true JP2017520774A5 (enExample) | 2018-05-10 |
| JP6953305B2 JP6953305B2 (ja) | 2021-10-27 |
Family
ID=54196451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Expired - Fee Related JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
| JP2021159462A Active JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159462A Active JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10450596B2 (enExample) |
| EP (1) | EP3122893B1 (enExample) |
| JP (2) | JP6953305B2 (enExample) |
| AU (1) | AU2015237241B2 (enExample) |
| CA (1) | CA2943823C (enExample) |
| WO (1) | WO2015148950A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| US10450596B2 (en) | 2014-03-28 | 2019-10-22 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
| CA3053356A1 (en) * | 2017-02-10 | 2018-08-16 | Health Research, Inc. | Targeting mitochondrial complex ii to reduce effects of chronic hypoxia |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| JP6977999B2 (ja) * | 2018-08-22 | 2021-12-08 | 国立大学法人京都大学 | 胚培養培地、及び胚培養方法 |
| FR3097739B1 (fr) * | 2019-06-25 | 2022-03-04 | Lnc Therapeutics | Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate |
| CN112830958B (zh) * | 2021-02-05 | 2022-06-14 | 山东大学 | 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US20060084123A1 (en) | 2001-12-13 | 2006-04-20 | Harris Adrian L | MN and hypoxia |
| AU2003302132B2 (en) * | 2002-11-21 | 2008-02-21 | Inverness Medical Switzerland Gmbh | Bodily fluid markers of tissue hypoxia |
| US20090186358A1 (en) | 2007-12-21 | 2009-07-23 | Wyeth | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof |
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| SE534542C2 (sv) | 2009-09-30 | 2011-09-27 | Calmark Sweden Ab | Testsystem för bestämning av hypoxiutlöst cellskada |
| WO2011050211A2 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US20120202883A1 (en) | 2011-01-20 | 2012-08-09 | Duke University | Effects of idh1 and idh2 mutations on the cellular metabolome |
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| EP2788763A4 (en) * | 2011-12-09 | 2015-10-07 | Metabolon Inc | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE |
| US8977473B2 (en) | 2012-08-29 | 2015-03-10 | Caterpillar Inc. | Pressure control strategy for dual fuel compression ignition engine and machine using same |
| US10450596B2 (en) | 2014-03-28 | 2019-10-22 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
-
2015
- 2015-03-27 US US15/129,167 patent/US10450596B2/en active Active
- 2015-03-27 AU AU2015237241A patent/AU2015237241B2/en not_active Ceased
- 2015-03-27 EP EP15768552.0A patent/EP3122893B1/en active Active
- 2015-03-27 JP JP2017502940A patent/JP6953305B2/ja not_active Expired - Fee Related
- 2015-03-27 WO PCT/US2015/023038 patent/WO2015148950A1/en not_active Ceased
- 2015-03-27 CA CA2943823A patent/CA2943823C/en active Active
-
2019
- 2019-06-25 US US16/452,297 patent/US11788112B2/en active Active
-
2021
- 2021-09-29 JP JP2021159462A patent/JP7208323B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520774A5 (enExample) | ||
| Han et al. | Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics | |
| Rello et al. | Sepsis: a review of advances in management | |
| Schelling | Tubular atrophy in the pathogenesis of chronic kidney disease progression | |
| Sapp et al. | The effects of moderate and high-intensity exercise on circulating markers of endothelial integrity and activation in young, healthy men | |
| JP2022008641A5 (enExample) | ||
| Pilz et al. | Associations of methylarginines and homoarginine with diastolic dysfunction and cardiovascular risk factors in patients with preserved left ventricular ejection fraction | |
| Maucler et al. | In vivo D-serine hetero-exchange through alanine-serine-cysteine (ASC) transporters detected by microelectrode biosensors | |
| Zhao et al. | The lncRNA MALAT1 participates in regulating coronary slow flow endothelial dysfunction through the miR-181b-5p–MEF2A–ET-1 axis | |
| Yu et al. | Correlation of plasma vascular endothelial growth factor and endostatin levels with symptomatic intra-and extracranial atherosclerotic stenosis in a Chinese Han population | |
| Okubo et al. | Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension | |
| Ma | Effect of anthracycline combined with aerobic exercise on the treatment of breast cancer. | |
| Dong et al. | ACE2 negatively regulates the Warburg effect and suppresses hepatocellular carcinoma progression via reducing ROS-HIF1α activity | |
| Alves et al. | Vascular reactivity and ACE activity response to exercise training are modulated by the+ 9/− 9 bradykinin B2 receptor gene functional polymorphism | |
| Kotlinska-Hasiec et al. | Disturbance in venous outflow from the cerebral circulation intensifies the release of blood-brain barrier injury biomarkers in patients undergoing cardiac surgery | |
| Kuo et al. | Effects of PGI2 analogues on Th1-and Th2-related chemokines in monocytes via epigenetic regulation | |
| Hamada et al. | Role of mitochondrial hydrogen peroxide induced by intermittent hypoxia in airway epithelial wound repair in vitro | |
| Chu et al. | Association between hypoxia-inducible factor-1a levels in serum and synovial fluid with the radiographic severity of knee osteoarthritis | |
| Beyer et al. | L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension | |
| JP2012521549A5 (enExample) | ||
| Yan et al. | Clinical Diagnostic Value of Serum GABA, NE, ET-1, and VEGF in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension | |
| Sultan et al. | Circulating prolidase activity in patients with myocardial infarction | |
| Wang et al. | Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker | |
| Phowira et al. | Subclinical thyrotoxicosis and cardiovascular risk: assessment of circulating endothelial progenitor cells, proangiogenic cells, and endothelial function | |
| Jalkanen et al. | Correlation between increasing tissue ischemia and circulating levels of angiogenic growth factors in peripheral artery disease |